ACEND

Vitamin D and Alzheimer’s: What a New Biomarker Study May Mean for Brain Health

April 8, 2026
Contributing Authors: Team TRILITY / ACEND

Vitamin D has long been associated with bone health and immune function, but new research is adding another dimension to the conversation: brain aging. A newly published study highlighted by Medical News Today reported that people with higher circulating vitamin D levels in midlife had lower tau burden years later on PET imaging, a biomarker pattern closely associated with Alzheimer’s disease. Importantly, the study found an association, not proof of cause and effect, and it did not show the same relationship with amyloid-beta. Still, it adds to a growing body of evidence suggesting that vitamin D status may matter more for long-term cognitive health than many people realize. 

That nuance matters. Alzheimer’s is complex, multifactorial, and unlikely to be prevented by any single nutrient. But biomarkers can offer early clues about the biological terrain that precedes cognitive decline. In the new Neurology Open Access paper, researchers followed 793 dementia-free adults and found that higher midlife vitamin D levels were associated with lower tau-PET burden roughly 16 years later. No meaningful association was seen with amyloid-beta, which suggests vitamin D may interact with some Alzheimer’s-related pathways more than others, or that timing and population age may shape what can be detected. 

Why is that interesting? Because tau is not just another lab marker. Tau accumulation is tied to neurodegeneration, neuronal dysfunction, and clinical progression in Alzheimer’s disease. If vitamin D status in midlife is related to tau burden later on, that opens the door to a more practical public-health question: should we be paying closer attention to vitamin D long before memory problems show up? The study does not answer that definitively, but it does support the idea that nutritional status during the “silent” years of brain aging may matter. 

This is not a small issue. In 2025, the Alzheimer’s Association estimated that 7.2 million Americans age 65 and older were living with Alzheimer’s dementia, and that number is projected to rise sharply in the coming decades. As the burden grows, interest is increasing in modifiable risk factors that may influence resilience before overt disease develops. Nutrition is only one part of that picture, but it is one of the parts people can actually do something about. 

What the broader science says about vitamin D and cognition

The new biomarker study did not appear in a vacuum. A 2025 dose-response meta-analysis of 22 observational studies, covering more than 53,000 participants, found that people in the lowest vitamin D category had a 49% higher risk of dementia than those in the highest category. The same analysis reported that each 10 nmol/L increase in vitamin D was associated with a modest reduction in dementia risk. That does not prove supplementation will prevent dementia, but it does reinforce a consistent epidemiologic signal: lower vitamin D status tends to track with worse cognitive outcomes. 

Other evidence points in a similar direction. A 2023 brain tissue study found that higher concentrations of 25(OH)D3 in several brain regions were associated with 25% to 33% lower odds of dementia or mild cognitive impairment before death. Interestingly, those brain vitamin D levels were linked with better cognition, even though they were not clearly associated with the classic neuropathology measures examined postmortem. That suggests vitamin D may be relevant to brain function and resilience even if its relationship to pathology is not simple or linear. 

Mechanistically, that makes sense. Vitamin D receptors are present in multiple brain regions involved in cognition, and vitamin D signaling has been linked to immune regulation, oxidative stress control, neuronal survival, calcium homeostasis, and neurotrophic support. Reviews published in 2025 describe vitamin D as a plausible neuroprotective factor because it appears to influence inflammatory tone, glial activity, mitochondrial stress, and broader cell-signaling pathways relevant to neurodegeneration. In other words, vitamin D may not be acting as a narrow “memory vitamin.” It may be part of a larger systems-level network that shapes the brain’s ability to tolerate aging, inflammation, and metabolic stress. 

But here is the caution: association is not intervention

This is where responsible interpretation matters. Observational findings and biomarker associations are not the same as randomized proof that taking vitamin D supplements will prevent Alzheimer’s disease. In fact, a 2025 randomized trial published in The Journals of Gerontology reported that five years of vitamin D3 supplementation did not reduce dementia incidence in a largely vitamin D-sufficient Finnish population. The authors also noted important limitations, including relatively low event numbers and limited power to detect modest effects, but the trial is still a useful reminder that the story is not settled. 

That tension between observational promise and mixed intervention data is common in nutrition science. Sometimes a nutrient is a marker of broader health status. Sometimes benefits are most likely in people who are deficient, not in already-replete populations. Sometimes timing matters more than dose, meaning a nutrient could be more relevant in midlife than late life. And sometimes nutrients work best as part of a network, rather than in isolation. The current vitamin D and Alzheimer’s literature supports cautious optimism, not hype. 

Why this matters for the ACEND perspective

At TRILITY, we look at chronic conditions through a systems lens. Neurodegenerative disease is not reducible to one pathway, one trigger, or one nutrient. It sits at the intersection of inflammation, oxidative stress, vascular function, mitochondrial strain, gut-immune signaling, and nutrient sufficiency. That is part of why vitamin D is so interesting: it touches several of those systems at once.

Vitamin D is included in ACEND not as a magic bullet, but as part of a broader nutritional framework designed to support foundational physiology. In the context of brain health, that means respecting the importance of sufficiency while also remembering the larger terrain. Vitamin D may help shape immune balance and neuroinflammatory tone, but so do polyphenols, antioxidant defenses, endothelial support, gut-derived signaling, and overall metabolic health. The emerging Alzheimer’s data fit well with that broader clinical philosophy: brain resilience is built through networks, not shortcuts.

This is also why “more” is not always the right message. The more responsible message is better status, better balance, and better context. A person who is low in vitamin D may benefit from restoring adequacy. A person with adequate levels may not gain the same benefit from escalating doses. And neither scenario eliminates the importance of exercise, sleep, glucose control, blood pressure management, and anti-inflammatory dietary patterns. The strongest prevention framework remains multifactorial. 

A smarter takeaway for readers

So what should readers do with this new study?

First, do not treat it as proof that vitamin D prevents Alzheimer’s. That is not what the paper showed. Second, do take it as another reason to care about nutrient adequacy earlier in life, not only after problems emerge. Third, recognize that vitamin D status is one piece of a broader prevention puzzle that includes inflammatory balance, cardiometabolic health, physical activity, and dietary pattern quality. 

For our readers, the more practical insight is this: foundational nutrition matters because the brain is not isolated from the rest of the body. The same systemic imbalances that affect inflammatory tone, vascular integrity, mitochondrial signaling, and gut-immune communication can also shape long-term cognitive health. Vitamin D belongs in that conversation, and this new biomarker study gives it even more relevance. But it belongs there as part of an integrated strategy, not as a standalone promise.

Therefore, the most evidence-aligned position today is that vitamin D deserves attention, especially when deficiency is common or suspected, and that long-term brain health is likely better served by comprehensive nutritional and lifestyle support than by single-nutrient thinking. That is precisely where TRILITY’s broader philosophy remains most useful.

References

  1. Mulligan MD, et al. Association of Circulating Vitamin D in Midlife With Increased Tau-PET Burden in Dementia-Free Adults. Neurology Open Access (2026). 
  2. Huang Y, et al. Association of vitamin D with risk of dementia: a dose-response meta-analysis of observational studies. Frontiers in Neurology (2025). 
  3. Shea MK, et al. Brain vitamin D forms, cognitive decline, and neuropathology in community-dwelling older adults. Alzheimer’s & Dementia (2023). 
  4. Lönnroos E, et al. The Effect of Vitamin D3 Supplementation on the Incidence of Dementia: A Randomized Controlled Trial. The Journals of Gerontology: Series A (2025). 
  5. Liu Y, et al. Neuroprotective Roles of Vitamin D: Bridging the Gap Between Experimental Evidence and Clinical Applications. International Journal of Molecular Sciences (2025). 
  6. Pietruszkiewicz J, et al. The Neuroprotective Potential of Vitamin D3. Nutrients (2025). 
  7. Alzheimer’s Association. 2025 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia (2025). 

Other articles you may enjoy

Astaxanthin and Cardiovascular Health: A Smarter Prevention Conversation
Cocoa Extract, Epicatechin, and Inflammation: What the Research Suggests
Micelles vs. Liposomes: Why Delivery Science Matters

Note: Always consult with a healthcare professional before considering any treatment options or significant dietary changes.